Q BioMed and Mannin Research move forward with MAN-19 therapeutic

6:58
 
Share
 

Manage episode 303230037 series 2891889
By Proactive Investors. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Q BioMed Inc CEO Denis Corin, CEO and Mannin Research Inc CEO Dr George Nikopoulos joined Proactive's Stephen Gunnion with news that the companies are poised to start clinical trials of their MAN-19 therapeutic in 2022. The MAN-19 therapeutic is a recombinant fusion protein and is being assessed to treat acute respiratory distress syndrome (ARDS), which is caused by viral infections in the lungs including coronavirus (COVID-19).

1567 episodes